Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles ..............714

Précis: Tumor formation assays and gene expression profiling complement genomic sequencing to identify rare but functionally relevant oncogenic alleles.

See commentary, p. 694

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma ..............727

Précis: High-throughput screening and a combined proteomic and genome-editing strategy identified the critical role of SRC in IDH mutant cholangiocarcinoma growth and survival.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors ..............740

Précis: The dual CDK4/6 kinase inhibitor abemaciclib has a favorable safety profile, achieves sustained target inhibition, and exhibits clinical activity as a single agent in a variety of solid tumors.

See commentary, p. 697
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer ............ 754
Précis: The differentiation state of KRAS-mutant lung cancer drives MEK inhibitor resistance via distinct pathways of receptor tyrosine kinase activation and confers sensitivity to dual MEK/FGFR1 blockade in mesenchymal-like cells.

ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia ....... 770
Précis: ASH1L-mediated dimethylation of H3K36 recruits LEDGF and MLL to chromatin and promotes MLL-associated gene transcription and leukemogenesis.
See commentary, p. 700

LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern ....... 784
Précis: GClnc1 was identified as an oncogenic lncRNA in gastric cancer that promotes tumorigenesis by acting as a scaffold to recruit the WDR5 and KAT2A complexes to the SOD2 promoter.

Correction
Correction: Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer ................. 802

Patnaik and colleagues report results of a first-in-human multicenter phase I dose-escalation trial to evaluate the safety and tolerability of abemaciclib, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in patients with advanced solid tumors. Abemaciclib was safe and well tolerated, with few serious adverse events, which allowed continuous dosing. Consistent with on-target inhibition of CDK4 and CDK6, which normally drive progression from G1- to S-phase by phosphorylating the RB tumor suppressor protein, a decrease in phosphorylated RB in epidermal keratinocytes was correlated with clinical response. Single-agent treatment with abemaciclib led to disease control (partial responses or stable disease) in patients with a range of advanced solid tumors, including breast cancer, non-small cell lung cancer, glioblastoma, melanoma, and colorectal cancer, supporting further clinical development of this compound. For details, please see the article by Patnaik and colleagues on page 740.

ON THE COVER Patnaik and colleagues report results of a first-in-human multicenter phase I dose-escalation trial to evaluate the safety and tolerability of abemaciclib, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in patients with advanced solid tumors. Abemaciclib was safe and well tolerated, with few serious adverse events, which allowed continuous dosing. Consistent with on-target inhibition of CDK4 and CDK6, which normally drive progression from G1- to S-phase by phosphorylating the RB tumor suppressor protein, a decrease in phosphorylated RB in epidermal keratinocytes was correlated with clinical response. Single-agent treatment with abemaciclib led to disease control (partial responses or stable disease) in patients with a range of advanced solid tumors, including breast cancer, non-small cell lung cancer, glioblastoma, melanoma, and colorectal cancer, supporting further clinical development of this compound. For details, please see the article by Patnaik and colleagues on page 740.
**CANCER DISCOVERY**

6 (7)


| Updated version | Access the most recent version of this article at: http://cancerdiscovery.aacrjournals.org/content/6/7 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/6/7. Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site. |